Related Experiment Video
Updated: Jun 19, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced
Mohammad Omar Faruk Shaikh1,2, Matthew M Schaefers1,2, Christina Merakou1,2
1Division of Critical Care Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Abstract:
The Gram-negative pathogen Pseudomonas aeruginosa is a common cause of pneumonia in hospitalized patients. Its increasing antibiotic resistance and widespread occurrence present a pressing need for vaccines. We previously showed that a P. aeruginosa type III secretion system protein, PopB, elicits a strong Th17 response in mice after intranasal (IN) immunization and confers antibody-independent protection against pneumonia in mice. In the current study, we evaluated the immunogenicity and protective efficacy in mice of the combination of PopB (purified with its chaperone protein PcrH) and OprF/I, an outer membrane hybrid fusion protein, compared with immunization with the proteins individually either by the intranasal (IN) or subcutaneous (SC) routes. Our results show that after vaccination, a Th17 recall response from splenocytes was detected only in mice vaccinated with PopB/PcrH, either alone or in combination with OprF/I. Mice immunized with the combination of PopB/PcrH and OprF/I had enhanced protection in an acute lethal P. aeruginosa pneumonia model, regardless of vaccine route, compared with mice vaccinated with either alone or adjuvant control. Immunization generated IgG titers against the vaccine proteins and whole P. aeruginosa cells. Interestingly, none of these antisera had opsonophagocytic killing activity, but antisera from mice immunized with vaccines containing OprF/I, had the ability to block IFN-γ binding to OprF/I, a known virulence mechanism. Hence, vaccines combining PopB/PcrH with OprF/I that elicit functional antibodies lead to a broadly and potently protective vaccine against P. aeruginosa pulmonary infections.
Insights
A novel vaccine combining Pseudomonas aeruginosa proteins PopB/PcrH and OprF/I enhances protection against pneumonia. This combination elicits functional antibodies, offering a potent strategy against this Gram-negative pathogen.
Area of Science:
- Immunology
- Microbiology
- Vaccinology
Background:
- Pseudomonas aeruginosa is a Gram-negative pathogen causing hospital-acquired pneumonia.
- Increasing antibiotic resistance necessitates effective vaccines.
- Previous work identified PopB protein's potential for intranasal (IN) immunization and protection.
Purpose of the Study:
- Evaluate the immunogenicity and protective efficacy of a combined PopB/PcrH and OprF/I vaccine.
- Compare intranasal (IN) and subcutaneous (SC) immunization routes.
- Assess the functional antibody responses and protection against P. aeruginosa pneumonia.
Main Methods:
- Mice were immunized with PopB/PcrH, OprF/I, or the combination via IN or SC routes.
- Assessed Th17 recall response from splenocytes.
- Evaluated protection in a lethal P. aeruginosa pneumonia model.
- Measured IgG titers, opsonophagocytic killing activity, and antibody blockade of IFN-γ binding to OprF/I.
Main Results:
- PopB/PcrH, alone or combined with OprF/I, induced Th17 recall responses.
- The PopB/PcrH and OprF/I combination provided enhanced protection against lethal pneumonia, irrespective of route.
- Vaccines generated IgG titers against P. aeruginosa components.
- Antisera containing OprF/I blocked IFN-γ binding to OprF/I, a virulence factor.
Conclusions:
- Vaccines combining PopB/PcrH and OprF/I elicit functional antibodies.
- This combination provides broadly and potently protective immunity against P. aeruginosa pulmonary infections.
- The developed vaccine strategy targets a critical need for effective P. aeruginosa vaccines.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
08:52Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Related Concept Videos
Vaccinations
Vaccines
Atypical Pneumonia